In a filing, Aurinia Pharmaceuticals Inc revealed its Director MacKay-Dunn R. Hector unloaded Company’s shares for reported $32316.0 on May 21 ’24. In the deal valued at $5.74 per share,5,630 shares were sold. As a result of this transaction, MacKay-Dunn R. Hector now holds 18,595 shares worth roughly $0.11 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Leversage Jill sold 5,610 shares, generating $32,201 in total proceeds. Upon selling the shares at $5.74, the Director now owns 12,918 shares.
Before that, Billen Daniel sold 5,252 shares. Aurinia Pharmaceuticals Inc shares valued at $30,146 were divested by the Director at a price of $5.74 per share. As a result of the transaction, Billen Daniel now holds 28,141 shares, worth roughly $0.16 million.
Oppenheimer downgraded its Aurinia Pharmaceuticals Inc [AUPH] rating to a Perform from a an Outperform in a research note published recently. Oppenheimer also remained covering AUPH and has increased its forecast on December 10, 2021 with a “an Outperform” recommendation from previously “Perform” rating. Oppenheimer revised its rating on October 28, 2021. It rated AUPH as “a Perform” which previously was an “an Outperform”.
Price Performance Review of AUPH
On Monday, Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] saw its stock jump 2.35% to $5.66. Over the last five days, the stock has gained 0.18%. Aurinia Pharmaceuticals Inc shares have fallen nearly -37.04% since the year began. Nevertheless, the stocks have fallen -40.55% over the past one year. While a 52-week high of $12.43 was reached on 01/10/24, a 52-week low of $4.71 was recorded on 04/18/24. SMA at 50 days reached $5.27, while 200 days put it at $6.95. A total of 0.78 million shares were traded, compared to the trading of 1.05 million shares in the previous session.
Levels Of Support And Resistance For AUPH Stock
The 24-hour chart illustrates a support level at 5.55, which if violated will result in even more drops to 5.45. On the upside, there is a resistance level at 5.73. A further resistance level may holdings at 5.80. The Relative Strength Index (RSI) on the 14-day chart is 58.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 10.53%. Stochastics %K at 70.18% indicates the stock is a holding.
#####
#####
#####
The most recent change occurred on January 25, 2021 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $35.
